| KURA ONCOLOGY DL-,0001 |
| USA |
| Gesundheit |
| US50127T1097 / A143UH |
| KUR (Frankfurt) / KURA (NASDAQ) |
| FRA:KUR, ETR:KUR, KUR:GR, NASDAQ:KURA |
| - |
| https://kuraoncology.com/ |
|
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of..
>Volltext.. |
| 607.09 Mio. EUR |
| 192.97 Mio. EUR |
| 69.62 Mio. EUR |
| -285.59 Mio. EUR |
| -267.54 Mio. EUR |
| -3.03 EUR |
| 22.05 Mio. EUR |
| 63.32 Mio. EUR |
| -100.75 Mio. EUR |
| 4.39 |
| -4.35% |
| -55.25% |
| - |
| - |
| - |
| - |
| KURA ONCOLOGY |
| 12.11.26 |
|